Phylloceuticals Appoints Biotech Veteran Nick Casale to Board of Directors

Phylloceuticals, Inc., a mission-driven biotechnology company pioneering plant-derived therapeutics for human health and wellness, proudly announces the appointment of Nick Casale to its Board of Directors.

Mr. Casale brings over three decades of global leadership in pharmaceutical engineering, technical operations, and facility development, with a distinguished career spanning some of the most innovative organizations in the life sciences sector.

Currently serving as Vice President, Global Facilities & Corporate Engineering at Ultragenyx Pharmaceutical Inc., Mr. Casale is recognized for his strategic oversight of complex biotech infrastructure and commitment to operational excellence. Prior to Ultragenyx, he held senior executive roles at the Center for Breakthrough Medicines, Amicus Therapeutics, and Novartis, where he led strategic planning for the Cell & Gene Therapy division, supporting the clinical and commercial manufacturing of CAR-T therapies.

Earlier in his career, Mr. Casale held engineering and operations leadership roles at Biogen, Brammer Bio, Bausch + Lomb, and Johnson & Johnson, where he played a key role in global pharmaceutical supply chain and facility modernization initiatives. A graduate of Drexel University, his career began as a Process Engineer at ConocoPhillips, focused on advanced composite materials for high-tech industries.

“Nick’s deep expertise in biologics manufacturing, facility engineering, and his track record of scaling operations make him an ideal strategic partner as we continue to grow our platform and bring innovative plant-based therapeutics to market,” said Susan Stipa, CEO of Phylloceuticals. “His insight will be invaluable as we expand our manufacturing capabilities and forge new global partnerships.”

Mr. Casale's appointment reinforces Phylloceuticals ’commitment to excellence in pharmaceutical development and sustainable innovation.